Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VC Enthusiasm For Gene Therapy Is Going Viral

Executive Summary

Audentes is the latest gene therapy start-up to land a large Series A round, taking $30 million to explore treatments for two rare muscle diseases. It’s another sign that VCs believe the risks around gene therapy are continuing to abate – and that pharmas aren’t far behind them.

Advertisement

Related Content

Celladon’s Mydicar Fails In Phase IIb, But Don’t Count Out Gene Therapy
Third Rock Takes On Parkinson's, Gene Therapy's Next Frontier
uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel